|
|
|
Welcome
to LymphomaLinks,
your monthly source of lymphoma news, research
updates, clinical trials and events sponsored by
The Leukemia & Lymphoma Society (LLS). For
even more information, regularly visit
LLS's Patient
Services and Disease
Information Web
sections. | |
 |
|
|
|
LLS
Features
::READ
MORE::
.....................................................................................................................................
Research
Roundup
::READ
MORE::
.....................................................................................................................................
IRC Question of
the Month
:: READ
MORE::
| |
|
|
Inspirational
Stories
 Learn how individuals touched
by blood cancer cope. LLS's LifeMosaic Web feature offers
hundreds of inspiring stories by patients and families. Read
them or submit your own. This
month, meet the Stephen
Patrick
Smith. |
Here to
Help
For
even more information, regularly visit the LLS
Web site,
www.LLS.org
,
where many of our education programs are
archived free of charge for convenient access
24/7.
If you haven't found what you're
looking for in LymphomaLinks , please
call our Information Resource Center (IRC) to
speak with trained information specialists. IRC
staff are available Monday through Friday, 9
a.m. to 6 p.m. ET, toll free at (800) 955-4572;
email
infocenter@lls.org
;
or click the "Live Patient Help" button on
the www.LLS.org
homepage.
| |
|
|
Commentary
Deborah Banker, Ph.D., reports
on talks at a recent cancer research
meeting.
Clinical
Trials
We
invite you to use
our LLS-supported TrialCheck®
Web site, a clinical trial search service
that offers patients and caregivers immediate
access to listings of
all lymphoma clinical trials. Answer
just a few simple questions and a list of
available clinical trials related to your cancer
will appear in an easy to read list of search
results.
You may also want to visit the
National Cancer Institute's Cancer
Trials Support Unit, providing resources and
information on phase III cancer treatment trials
supported by the National Cancer
Institute
. ::SELECTED TRIALS::
Newsfeeds &
Podcasts
Now you can get
RSS Feeds and Podcasts from LLS.
::CLICK HERE TO SIGN
UP::
Free
eNewsletters
Free LLS
eNewsletters deliver the latest information on
research and treatment options, patient services
programs and fundraising events.
:: CLICK HERE TO SIGN
UP::
| | | |
| 
| | | |
|
|
|
Emerging
Therapies in Leukemia, Lymphoma & Myeloma
Register now for this free telephone
education program on Tuesday, June 16, noon -
1:30 p.m. ET. The guest speakers are Gail
J. Roboz, MD and John P. Leonard, MD both
from Weill Medical College of Cornell
University/New York-Presbyterian Hospital, New
York, NY and Robert Z. Orlowski, MD, PhD from
The University of Texas, MD Anderson Cancer
Center, Houston,
TX.
Update
on Mantle Cell Lymphoma
Register now for
this free telephone education program on
Thursday, June 18, noon - 1:30 p.m. ET. The
guest speaker is Owen A. O'Connor, MD from
Herbert Irving Comprehensive Cancer Center, New
York-Presbyterian Hospital, Columbia University,
New York, NY.
NHL:
Understanding Diagnosis and Making Treatment
Decisions
Register now for this free
telephone education program on Wednesday, June
24, noon - 1:30 p.m. ET. The guest speaker is
Steven H. Bernstein, MD from the James P.
Wilmont Cancer Center, University of Rochester
Medical Center, Rochester,
NY.
My
Personal Lymphoma Journey
This unique
interactive Web program follows the stories and
experiences of lymphoma survivors, including a
new story of a follicular lymphoma survivor. The
guest physician is John P. Leonard, MD, of
Weill Cornell Medical College of Cornell
University. We hope this program helps you to
learn more about the lymphoma journey, and
resources that are available to you and other
lymphoma
survivors.
My
Clinical Trials Journey
Personalized and
interactive program that follows the stories and
experiences of three cancer survivors who have
participated in clinical trials, including a
lymphoma survivor. Their stories of hope and
determination are compelling. Ann Pirro,
Physician's Assistant at Queens Medical Center,
Fresh Meadows, NY, provides expert insights
along the
way.
Clinical Trial Recruitment -- LLS,
through its Therapy Accelerator Program,
is collaborating on several clinical
trials that are actively recruiting.
Two of these trials are designed for Lymphoma
patients (recruiting in Cleveland, Ohio in the
States and Calgary and Toronto in Canada).
For more information about these trials, see the
Therapy
Accelerator Program section of lls.org.
LLS
Advocacy
LLS's
advocacy team represents the needs of cancer
patients and their families in Washington,
DC and state capitals throughout the United
States. We need your help. Join our
Advocates Network and make your voice heard.
Take Action: Urge
Congress to Co-Sponsor Access to Cancer Clinical
Trials
Patient
Services Survey
Please give us your
feedback by completing LLS Disease &
Treatment Publications - Survey for Patients,
Family and Friends.
LLS Blog
Showcase your support:
- Read leukemia survivor, Debbie
Gill's book, Living
a Miracle, and be inspired by her
battle. All proceeds from the sale of this book
benefit The Leukemia & Lymphoma
Society.
Learn the many ways you can help advance the
LLS mission, including making a donation.
Find
out more about our other
eNewsletters.
> Back to the
top
| |
|
Physical Activity and
Quality of Life in Adult Survivors of
Non-Hodgkin's Lymphoma ::READ
MORE::
Autologous
SCT with a Dose-Reduced BU and CY Regimen in
Older Patients with non-Hodgkin's Lymphoma
::READ
MORE::
The addition of
Radiotherapy to Chemotherapy Does Not Improve
Outcome of Early Stage Hodgkin's Lymphoma
Patients: A Retrospective Long-Term Follow-Up
Analysis of a Regional Italian Experience
::READ
MORE::
Outcome of Deferred
Initial Therapy in Mantle-Cell Lymphoma
::READ
MORE::
Phase II Study of
Risk-Adapted Therapy of Newly Diagnosed,
Aggressive non-Hodgkin Lymphoma Based on
Midtreatment FDG-PET Scanning ::READ
MORE::
Reduced Intensity
Conditioning Allogeneic Stem Cell
Transplantation for Hodgkin's Lymphoma:
Identification of Prognostic Factors Predicting
Outcome ::READ
MORE::
>Back to the
top
| |
Selected
Trials
Siplizumab, Combination
Chemotherapy, and Rituximab in Treating Patients
With T-Cell or Natural Killer-Cell Non-Hodgkin
Lymphoma ::READ MORE::
Phase
II: Bendamustine Combined With Rituximab for
Patients With Relapsed or Refractory Diffuse
Large B-Cell Lymphoma (904) ::READ
MORE::
Phase II:
Rituximab, Ifosfamide, Carboplatin, and
Etoposide (RICE) Followed by Gallium Nitrate,
Rituximab and Dexamethasone (GARD) for Relapsed
or Refractory Diffuse Large B-Cell
Lymphoma ::READ
MORE::
A Phase III Study
of Galiximab + Rituximab Versus Rituximab +
Placebo in Follicular Non-Hodgkin's Lymphoma
(NHL) ::READ
MORE::
Phase II Study of
Oral Panobinostat in Adult Patients With
Relapsed/Refractory Classical Hodgkin's
Lymphoma ::READ
MORE::
A Phase II Study
to Evaluate Efficacy and Safety of P276-00 in
Relapsed and/or Refractory Mantle Cell
Lymphoma ::READ
MORE::
Safety and
Efficacy of RAD001 in Patients With Velcade®
Refractory Mantle Cell Lymphoma ::READ
MORE::
A Phase II Study
to Determine the Efficacy and Safety of
Lenalidomide in Patients With Mantle Cell NHL
Who Have Relapsed or Progressed After Treatment
With Bortezomib or Are Refractory to Bortezomib.
The "EMERGE" Trial ::READ
MORE::
Laboratory-Treated Peripheral Blood
Lymphocytes With or Without Chemotherapy in
Treating Patients With Progressive B-Cell
Lymphoma or Chronic Lymphocytic Leukemia
::READ
MORE::
>Back to the
top
| |
| IRC
Question of
the Month | 
Q: My dad told me that
he has chosen to take part in a clinical trial
for his lymphoma treatment. Are clinical trials
safe?
A: U.S.
cancer clinical trials are carefully designed
and monitored to give participants such as your
dad the safest, and potentially most effective,
treatment outcomes. All trials follow strict
scientific and ethical guidelines. Every
clinical trial has an action plan, called a
"protocol." Whether a cancer clinical trial
takes place at just a few locations or at sites
across the U.S., the same protocol is used by
every doctor at each treatment center taking
part in the trial.
A cancer clinical trial is divided into four
phases. Healthcare providers carefully check
patient safety in all phases of a trial. In
phase 1 trials, a treatment is tested in a very
small group of patients to establish safety and
dose. In phase 2 trials, treatment is tested in
a larger group of patients to establish whether
and how well the treatment works. Phase 3 trials
compare a "treatment group" (large numbers of
patients who receive the "study" treatment) to a
"control group" (large numbers of patients who
are being treated with the best standard
treatment). For treatments that have already
been approved by the FDA following phase 3
trials, phase 4 studies are often done to gather
more information.
Advances in treatment for lymphoma depend on
clinical trials. So, being treated in a clinical
trial also means that your dad will participate
in a research study to improve the care and
treatment of people with cancer. Here are 10
important questions for people to ask their
doctors about whether treatment in a specific
clinical trial is right for them:
1. What is the purpose of this clinical
trial and why do you think it may be effective
for me?
2. How is the "study" treatment
different from the best standard treatment
available to me?
3. What are the
expected benefits and risks of the "study"
treatment versus the standard treatment?
4. Who will be in charge of my
care?
5. Where will I be
treated?
6. How do I know whether my
insurance will cover the costs of the clinical
trial? Will I have to pay
for
any part of the
trial such as tests or the study
drug?
7. Can I talk to other people in
the study?
8. How long will I be treated
in the study?
9. How and when will I
know if my treatment is or isn't working?
10. If the study treatment is not
effective for me, how will this affect my other
treatment options?
People who decide to consider participating
in a trial will have more opportunity to gather
information. The "informed consent" process
gives potential participants a chance to ask
more questions, to read over written information
at home, and to discuss it further with their
doctors, families and other trusted
advisors. People who need the services of
a language interpreter may request one.
The Information
Resource Center (IRC) staff is skilled in
providing assistance to people considering
clinical trial options. You may reach the IRC by
calling (800) 955-4572, using Live
Help or by sending an email.
Visitors to the LLS Web site can find clinical
trials near them through the LLS-supported TrialCheck®
Web site, a clinical trial search service that
provides access to blood cancer clinical trials
listings.
For more information view, print or order the
free LLS booklet Understanding
Clinical Trials for Blood Cancers, see the
Web page Making
Treatment Decisions and participate in
the interactive Web video My
Clinical Trials Journey on the LLS
Web
site.
Please call
our Information Resource Center (IRC) to speak
with a trained information specialist. IRC staff
are available Monday through Friday, 9 a.m. to 6
p.m. ET, toll free at (800) 955-4572. Contact us
online or click the "Live
Patient Help" button on the www.LLS.org
homepage.
> Back to the
top
| |
| | | |
|
|
 |
Supported by an
unrestricted
educational grant
from
 |
 |
|
Contact Us: The
Leukemia & Lymphoma Society, 1311 Mamaroneck
Ave., White Plains, NY 10605, (800)
955-4572
|
|
| Visit our e-Store
& Special Offers page where you can
support businesses that support
LLS. | | | | | |
|
| | | |
